127 related articles for article (PubMed ID: 36543249)
1. Factors associated with Pharmaceutical Benefits Advisory Committee decisions for listing medicines for diabetes and its associated complications.
Haque MM; Gumbie M; Gu M; Dissanayake G
Aust Health Rev; 2023 Apr; 47(2):139-147. PubMed ID: 36543249
[TBL] [Abstract][Full Text] [Related]
2. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
Chim L; Kelly PJ; Salkeld G; Stockler MR
Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
[TBL] [Abstract][Full Text] [Related]
3. Analysis of PBAC submissions and outcomes for medicines (2010-2018).
Lybrand S; Wonder M
Int J Technol Assess Health Care; 2020 Jun; 36(3):224-231. PubMed ID: 32524923
[TBL] [Abstract][Full Text] [Related]
4. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
Sinha Y; Brien JA; Craig JC
J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
[TBL] [Abstract][Full Text] [Related]
5. Analysis of sponsor hearings on health technology assessment decision making.
Flowers M; Lybrand S; Wonder M
Aust Health Rev; 2020 Apr; 44(2):258-262. PubMed ID: 31072455
[TBL] [Abstract][Full Text] [Related]
6. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.
Turkstra E; Bettington E; Donohue ML; Mervin MC
Int J Technol Assess Health Care; 2017 Jan; 33(4):521-528. PubMed ID: 28703092
[TBL] [Abstract][Full Text] [Related]
7. Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.
Phan YHL; De Abreu Lourenco R; Haas M; van der Linden N
Mult Scler Relat Disord; 2018 Oct; 25():144-149. PubMed ID: 30077086
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
Wonder M; Dunlop S
Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
[TBL] [Abstract][Full Text] [Related]
9. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
Wonder MJ; Neville AM; Parsons R
Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
[TBL] [Abstract][Full Text] [Related]
10. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
Scuffham PA; Whitty JA; Mitchell A; Viney R
Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
[TBL] [Abstract][Full Text] [Related]
11. How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.
Bailey C; Dalziel K; Cronin P; Devlin N; Viney R;
Pharmacoeconomics; 2022 Feb; 40(2):157-182. PubMed ID: 34738210
[TBL] [Abstract][Full Text] [Related]
12. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
Kim H; Byrnes J; Goodall S;
Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
[TBL] [Abstract][Full Text] [Related]
13. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
George B; Harris A; Mitchell A
Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
[TBL] [Abstract][Full Text] [Related]
15. Relationship between financial impact and coverage of drugs in Australia.
Mauskopf J; Chirila C; Masaquel C; Boye KS; Bowman L; Birt J; Grainger D
Int J Technol Assess Health Care; 2013 Jan; 29(1):92-100. PubMed ID: 23217275
[TBL] [Abstract][Full Text] [Related]
16. Analysis of consumer comments into PBAC decision-making (2014-9).
Tjeuw E; Wonder MJ
Int J Technol Assess Health Care; 2022 Feb; 38(1):e18. PubMed ID: 35115073
[TBL] [Abstract][Full Text] [Related]
17. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
18. Delays in access to affordable medicines: putting policy into perspective.
Pearce A; van Gool K; Haywood P; Haas M
Aust Health Rev; 2012 Nov; 36(4):412-8. PubMed ID: 23062753
[TBL] [Abstract][Full Text] [Related]
19. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia.
Robertson J; Walkom EJ; Bevan MD; Newby DA
BMC Public Health; 2013 May; 13():489. PubMed ID: 23687910
[TBL] [Abstract][Full Text] [Related]
20. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
Lexchin J; Mintzes B
Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
